EDAP TMS SA: management transactions · United States · SEC (Form 4)

About EDAP TMS SA

EDAP TMS SA is a French medical device company focused on minimally invasive ultrasound-based therapies. The company is listed on the Nasdaq in the United States, making it relevant for U.S. equity investors even though its corporate roots and headquarters are in Vaulx-en-Velin, near Lyon, France. Founded in 1979, EDAP has built its business over several decades around therapeutic ultrasound and urology, gradually sharpening its strategic focus toward higher-value robotic energy-based therapies. The company’s core investment thesis is now centered on Focal One®, its robotic High-Intensity Focused Ultrasound (HIFU) platform for prostate tissue ablation. Focal One integrates imaging, robotics, and precise non-invasive energy delivery to target tissue without open surgery. That positions EDAP as a niche but important player in focal therapy for prostate cancer, a market where physicians are looking for less invasive options that may preserve quality-of-life outcomes relative to traditional radical procedures. This is where EDAP differentiates itself: not as a broad medtech conglomerate, but as a specialized technology company with a clinically oriented platform and a focused commercial message. EDAP still maintains legacy or non-core activities, including extracorporeal shock wave lithotripsy (ESWL) systems for urinary stones and certain third-party product distribution businesses. However, management has clearly been prioritizing HIFU as the main growth engine. The company’s international footprint includes direct operations and commercialization in the United States, Europe, and select other markets, supported by a commercial and clinical network that helps drive system placements and recurring disposables revenue. Recent developments have reinforced that strategic direction. In 2025, EDAP launched Focal One i, a next-generation robotic HIFU system, and continued to report clinical and commercial progress in the U.S. market. In March 2026, the company reported record fourth-quarter and full-year 2025 HIFU revenue, highlighted continued growth in Focal One system placements and U.S. procedures, and reiterated 2026 guidance pointing to further expansion of the core HIFU business. For investors, EDAP remains a specialized growth story in medical technology, with key watchpoints including procedure adoption, regulatory milestones, reimbursement dynamics, and the pace of commercial scaling in the United States.